Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

1,711

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

July 31, 2010

Conditions
Hypertension
Interventions
DRUG

Azilsartan medoxomil and chlorthalidone

Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

DRUG

Azilsartan medoxomil and chlorthalidone

Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

DRUG

Azilsartan medoxomil and chlorthalidone

Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

DRUG

Azilsartan medoxomil and chlorthalidone

Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

DRUG

Azilsartan medoxomil and chlorthalidone

Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

DRUG

Azilsartan medoxomil and chlorthalidone

Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

DRUG

Chlorthalidone

Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

DRUG

Chlorthalidone

Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

DRUG

Azilsartan medoxomil

Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

DRUG

Azilsartan medoxomil

Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

DRUG

Azilsartan medoxomil

Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

Trial Locations (99)

Unknown

Birmingham

Columbiana

Tuscaloosa

Chandler

Phoenix

Scottsdale

Tucson

Little Rock

Buena Park

Carmichael

Costa Mesa

Irvine

Palm Springs

Riverside

Sacramento

San Diego

Vista

Walnut Creek

Middletown

Bradenton

Deerfield Beach

Fort Lauderdale

Hallandale

Hialeah

Jacksonville

Longwood

Miami

Ocala

Ormond Beach

St. Petersburg

Atlanta

Buffalo Grove

Libertyville

Melrose Park

Fishers

Indianapolis

Erlanger

Madisonville

Paducah

Rockville

Ann Arbor

Chesterfield

St Louis

Omaha

Henderson

Brick

Margate City

Albuquerque

Endwell

Cary

Winston-Salem

Cincinnati

Cleveland

Columbus

Dayton

Lyndhurst

Willoughby Hills

Oklahoma City

Ashland

Altoona

Bensalem

Feasterville

Jenkintown

Sellersville

Warminster

Charleston

Florence

Murrells Inlet

Simpsonville

Spartanburg

Clarksville

New Tazewell

Austin

Bellaire

Dallas

Houston

McKinney

Richardson

San Antonio

Magna

West Jordan

Arlington

Virginia Beach

Oregon

Santiago

Temuco

Aguascalientes

Mexico City

Mérida

Bellavista

Chiclayo

Jesus Maria

Miraflores

San Borja

San Martín de Porres

Trujillo

Umacollo

Moscow

Saint Petersburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00847626 - Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension | Biotech Hunter | Biotech Hunter